Morphic Holding Inc - ESG Rating & Company Profile powered by AI
This assessment of Morphic Holding Inc employs intelligence from across the web and also from available documents by Morphic Holding Inc. The page is a free Sustainability analysis for Morphic Holding Inc. Browse to the end of this webpage for potential risks for Morphic Holding Inc based on industry, location and marketcap.
Morphic Holding Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.4; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.3.
0.4
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1924 | Sigma Healthcare Ltd | 0.5 | Low |
| 1924 | Uni-Bio Science Group Ltd | 0.5 | Low |
| 1952 | Morphic Holding Inc | 0.4 | Low |
| 1952 | CFR Pharmaceuticals SA | 0.4 | Low |
| 1952 | CellSource Co Ltd | 0.4 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Morphic Holding Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Morphic Holding Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Morphic Holding Inc report the average age of the workforce?
Sign up for free to unlockDoes Morphic Holding Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Morphic Holding Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Morphic Holding Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Morphic Holding Inc offer flexible work?
Sign up for free to unlockDoes Morphic Holding Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Morphic Holding Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Morphic Holding Inc conduct supply chain audits?
Sign up for free to unlockDoes Morphic Holding Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Morphic Holding Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Morphic Holding Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Morphic Holding Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Morphic Holding Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Morphic Holding Inc disclose water use targets?
Sign up for free to unlockDoes Morphic Holding Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Morphic Holding Inc have a product recall in the last two years?
Sign up for free to unlockDoes Morphic Holding Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Morphic Holding Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Morphic Holding Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Morphic Holding Inc disclose parental leave metrics?
Sign up for free to unlockDoes Morphic Holding Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Morphic Holding Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Morphic Holding Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Morphic Holding Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Morphic Holding Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Morphic Holding Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Morphic Holding Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Morphic Holding Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Morphic Holding Inc disclose its waste policy?
Sign up for free to unlockDoes Morphic Holding Inc report according to TCFD requirements?
Sign up for free to unlockDoes Morphic Holding Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Morphic Holding Inc disclose energy use targets?
Sign up for free to unlockDoes Morphic Holding Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Morphic Holding Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Morphic Holding Inc
These potential risks are based on the size, segment and geographies of the company.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.